KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Short-term Investments (2016 - 2023)

BeOne Medicines (ONC) has disclosed Short-term Investments for 9 consecutive years, with $2.6 million as the latest value for Q4 2023.

  • On a quarterly basis, Short-term Investments fell 99.61% to $2.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $2.6 million, a 99.61% decrease, with the full-year FY2023 number at $2.6 million, down 99.61% from a year prior.
  • Short-term Investments was $2.6 million for Q4 2023 at BeOne Medicines, down from $107.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $3.3 billion in Q4 2020 to a low of $2.6 million in Q4 2023.
  • A 5-year average of $1.5 billion and a median of $1.3 billion in 2020 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: soared 796.21% in 2020, then crashed 99.61% in 2023.
  • BeOne Medicines' Short-term Investments stood at $364.7 million in 2019, then skyrocketed by 796.21% to $3.3 billion in 2020, then tumbled by 31.41% to $2.2 billion in 2021, then plummeted by 70.33% to $665.3 million in 2022, then plummeted by 99.61% to $2.6 million in 2023.
  • Per Business Quant, the three most recent readings for ONC's Short-term Investments are $2.6 million (Q4 2023), $107.0 million (Q3 2023), and $665.3 million (Q4 2022).